NCT03052634: RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer

NCT03052634
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine Kinase Inhibitor, Chemotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable brain metastases
https://ClinicalTrials.gov/show/NCT03052634

Comments are closed.

Up ↑